Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 126,402

Document Document Title
WO/2017/130108A1
The present invention relates to a formulation for use in treating migraine aura comprising, as active ingredients, an extract of Tanacethum parthenium, magnesium cations, 5-hydroxy-tryptophan. The present invention further relates to a ...  
WO/2017/129782A1
The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2...  
WO/2017/130859A1
A neuronal cell death inhibitor having as an active ingredient a bacterium belonging to Bifidobacterium longum, such as Bifidobacterium longum subspecies infantis LMG 23728 or Bifidobacterium longum subspecies longum ATCC 15707, or a cul...  
WO/2017/132432A8
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORĪ³. Also provided are pharmaceutica...  
WO/2017/131171A1
Provided is a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. [In formula (I): A1 is a methylene group, and the like; A2 is a methylene group or an oxygen atom; A3 is an azetidinyl group, pyrro...  
WO/2017/132432A1
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...  
WO/2017/129061A1
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable sa...  
WO/2017/129987A1
Compositions comprising a nutritionally or pharmaceutically effective dosage of an extract of Salvia officinalis and an acceptable carrier are provided. The compositions show particular potential in the treatment of age-related pathologi...  
WO/2017/130933A1
The purpose of the present invention is to provide a therapeutic agent for neurodegenerative diseases, more specifically to provide a neuroprotective therapeutic agent, for example, a novel therapeutic agent for ophthalmic neurodegenerat...  
WO/2017/132675A1
This disclosure relates to method for treating Sanfilippo Syndrome B (also Mucopolysaccharidosis III B, MPSIIIB) by enzyme replacement therapy.  
WO/2017/129046A1
Provided in the present invention are a compound of polyethylene glycol and opioid as shown in general formula (I), and a pharmaceutical composition comprising the compound. By means of covalently bonding a plurality of opioids on a deri...  
WO/2017/132127A1
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73), ANAVEX1-41 and/or Anavex19-144 in a method of treatment for neurodevelopmental disorders. Particular reference...  
WO/2017/124835A1
The present invention discloses a compound (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compound of the present invention provides excellent interference of a binding of NRF2 by KEAP...  
WO/2017/125919A1
The present invention provides a composition comprising a synergistic combination of melatonin, valerenic acid and carnosic acid. The composition may be used in the treatment and prevention of several different disorders including inflam...  
WO/2017/125841A1
The present invention relates to pharmaceutical compositions of Teriflunomide or pharmaceutically acceptable salts thereof and method of preparation of such compositions. Typically, the composition according to present invention comprise...  
WO/2017/126700A1
Provided are a pharmaceutical composition containing a VNUT inhibitor and a method using a VNUT inhibitor, each of which can be employed for treating or preventing a disease or condition selected from the group consisting of non-alcoholi...  
WO/2017/124970A1
Provided are a dicaffeoyl-spermidine derivative glycoside, a preparation method therefor and a use. Biological activity tests show that the dicaffeoyl-spermidine derivative glycoside has antioxidant activity and antiviral activity, the a...  
WO/2017/126645A1
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...  
WO/2017/126648A1
A therapeutic method whereby it becomes possible to reduce adverse side effects and the QOL of a patient can be improved while exerting a therapeutic effect on pain has been demanded. When N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-...  
WO/2017/125065A1
Use of an algal proteoglycan extract and a composition comprising the same in the manufacture of a medicament for treating or preventing tumor, pain, inflammation or diseases mediated by inflammatory factors.  
WO/2017/124969A1
Provided are a dicaffeoyl-spermidine cyclic derivative and a use. Biological activity tests show that the dicaffeoyl-spermidine cyclic derivative has anti-senile dementia activity and antioxidant activity, the activity of the derivative ...  
WO/2017/125932A1
The present invention is directed to indoline derivatives and salts thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders associated with at least one of oxidative stress, an immune response, ...  
WO/2017/127417A1
The invention relates to phosphopantothenate compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel compounds of the invention.  
WO/2017/126655A1
The present invention provides: a method for screening for a pain-preventing substance, characterized by comprising selecting a substance capable of inhibiting the expression of Robo4 or a substance capable of inhibiting the binding betw...  
WO/2017/124213A1
Provided is a joint application of a statin and a adrenocortical hormone for preparing a pharmaceutical product for treating a chronic subdural hematoma. The pharmaceutical product provided by the invention is able to accelerate hematoma...  
WO/2017/125924A1
The present invention is primarily directed to a therapeutic composition comprising caffeine, valerenic acid and 5-hydroxytryptophan (5-HTP). Additional herbal material and other natural products may also be present in the composition. T...  
WO/2017/124921A1
The present invention provides a walnut oligopeptide powder, and a preparation method and application thereof. The oligopeptide powder has a peptide content of 80 wt% or higher, wherein 95% or more of the peptides have a molecular weight...  
WO/2017/126635A1
The purpose of the present invention is to provide a heterocyclic compound having an antagonistic activity on prostaglandin E2 (PGE2) receptor subtype 2. A compound represented by formula (I) [wherein each symbol is as defined in the des...  
WO/2017/124949A1
The present invention relates to flavanone derivatives and a preparation method and use thereof, and in particular relates to the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composi...  
WO/2017/123791A1
The present invention features a neural organoid that recapitulates in vitro most characteristics of the brain (e.g., human), and methods of using this neural organoid to study disease and to identify therapeutic agents for the treatment...  
WO/2017/121646A1
The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/122722A1
The present invention provides: a compound represented by formula (1) as a pharmaceutical agent which is useful as a neuroregeneration promoting agent [in the formula, R1-L- represents R1-OC(O)-, etc., R1 represents a hydrogen atom, an o...  
WO/2017/121649A1
The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-l,3-diaza- spiro-[4.5]-decane derivatives of general formula (I), their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/121379A1
The present application relates to a p-toluenesulfonate salt for regulating a kinase compound, and crystals thereof, and specifically, to an N-{3-[3-(9H-purine-6-group)pyridine-2-group amino]-4-chlorine-2-fluorophenyl}-3-fluoropropane-1-...  
WO/2017/124037A1
The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.  
WO/2017/123822A1
The present invention provides, in some embodiments, compounds and compositions that are SQOR substrates, and which are useful in increasing thiosulfate, decreasing hydrogen sulfide, and/or preventing an increase in hydrogen sulfide in a...  
WO/2017/121650A1
The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/121838A1
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 /CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of c...  
WO/2017/122789A1
Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which ...  
WO/2017/121647A1
The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/122754A1
A compound represented by general formula (I), a tautomer or stereoisomer of said compound, or a pharmaceutically acceptable salt thereof, or a solvate of these is used as a voltage-dependent T-type calcium channel inhibitor. (In the for...  
WO/2017/121648A1
The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]- decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.  
WO/2017/123820A1
The invention discloses methods of determining demand on the sulfide oxidation pathway in a human, by measuring a level of H2S, thiosulfate, and/or glutathione persulfide in a biological sample from the human. Further disclosed are metho...  
WO/2017/119455A1
Provided is a prophylactic or therapeutic agent for autism spectrum disorder, said agent comprising compound (I) that has affinity to melatonin receptors. A compound represented by formula (I) [wherein the meaning of each symbol is as de...  
WO/2017/119481A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a particular cyclic dipeptide or a s...  
WO/2017/118307A1
The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.  
WO/2017/120409A1
Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae (I), (II), or (III), which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydroc...  
WO/2017/118375A1
Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.  
WO/2017/120417A1
Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in ...  
WO/2017/119456A1
The present invention provides a prophylactic or therapeutic agent for delirium, containing a compound (I) having an affinity for a melatonin receptor. A compound represented by the formula [wherein, each symbol is as defined in the desc...  

Matches 351 - 400 out of 126,402